Domus Diagnostics
Domus Diagnostics is dedicated to developing affordable, user-friendly, accurate, and rapid infectious disease tests to address current and future public health crises worldwide. They focus on combining innovative chemistry with simple manufacturing technology to create low-cost diagnostic solutions for all settings, including at-home, clinics, and central laboratories. Their mission is to improve global health by providing accessible testing options that meet high performance standards.
Industries
Nr. of Employees
small (1-50)
Domus Diagnostics
Patents
System and method for enhancing visualization of colorimetric assay readouts
US-12536631-B2
View Details
System and method for enhancing visualization of colorimetric assay readouts
US-12536631-B2
View DetailsProducts
Disposable, instrument-free at-home nucleic acid test
A single-use, laminate-format, instrument-free molecular diagnostic intended for home use that integrates sample collection, one-pot isothermal amplification, chemical heating, and visual readout with a ~30 minute time-to-result.
Low-cost, no-service desktop instrument for clinics
A compact, low-cost desktop instrument and associated assays intended for clinic settings that reduces operator burden and delivers rapid NAAT results with simplified workflows.
Lab-developed one-step assays for central laboratories
One-step, one-temperature nucleic acid assays adapted for central lab deployment and for integration with established analyzer platforms with potential for very short TAT.
Disposable, instrument-free at-home nucleic acid test
A single-use, laminate-format, instrument-free molecular diagnostic intended for home use that integrates sample collection, one-pot isothermal amplification, chemical heating, and visual readout with a ~30 minute time-to-result.
Low-cost, no-service desktop instrument for clinics
A compact, low-cost desktop instrument and associated assays intended for clinic settings that reduces operator burden and delivers rapid NAAT results with simplified workflows.
Lab-developed one-step assays for central laboratories
One-step, one-temperature nucleic acid assays adapted for central lab deployment and for integration with established analyzer platforms with potential for very short TAT.
Services
Collaborative development engagements to adapt the platform into low-cost, no-service desktop instruments suitable for clinic use.
Development of lab-developed one-step tests and dedicated assays for integration with established analyzer platforms to achieve rapid TAT.
Support and execution of clinical testing activities to prepare multiplex NAATs for regulatory submissions and global authorization pathways.
Design and implementation planning for high-throughput, low-cost production including roll-to-roll templates and pilot manufacturing approaches to reach targeted per-test COGS.
Collaborative development engagements to adapt the platform into low-cost, no-service desktop instruments suitable for clinic use.
Development of lab-developed one-step tests and dedicated assays for integration with established analyzer platforms to achieve rapid TAT.
Support and execution of clinical testing activities to prepare multiplex NAATs for regulatory submissions and global authorization pathways.
Design and implementation planning for high-throughput, low-cost production including roll-to-roll templates and pilot manufacturing approaches to reach targeted per-test COGS.
Expertise Areas
- Point-of-care and at-home molecular diagnostics
- Isothermal NAAT (RT-LAMP) development
- Lyophilized reagent formulation and ambient stability
- Disposable laminate device engineering
Key Technologies
- One-pot RT-LAMP (isothermal amplification)
- Lyophilization of reagents
- Chemical heat regulation for isothermal control
- Laminate roll-to-roll manufacturing
News & Updates
Domus was awarded $2.4M by NIH RADx Tech Program to support development of ultra-low-cost, at-home diagnostic tests.
Domus announced clinical testing of its COVID-19 testing platform that can be used anywhere without power or cold chain logistics.
Domus is developing a highly affordable, accurate, and easy-to-use nucleic acid amplification test for infectious diseases, supported by NIH funding.
A lyophilized colorimetric RT-LAMP test kit for rapid, low-cost, at-home molecular testing of SARS-CoV-2 and other pathogens.
Received a multi-million dollar grant from NIH RADx Tech Program to develop ultra-low-cost, at-home COVID-19 tests.
Domus was awarded $2.4M by NIH RADx Tech Program to support development of ultra-low-cost, at-home diagnostic tests.
Domus announced clinical testing of its COVID-19 testing platform that can be used anywhere without power or cold chain logistics.
Domus is developing a highly affordable, accurate, and easy-to-use nucleic acid amplification test for infectious diseases, supported by NIH funding.
A lyophilized colorimetric RT-LAMP test kit for rapid, low-cost, at-home molecular testing of SARS-CoV-2 and other pathogens.
Received a multi-million dollar grant from NIH RADx Tech Program to develop ultra-low-cost, at-home COVID-19 tests.